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Abstract 
The design, synthesis and evaluation of a small series of potent amphiphilic norbornane antibacterial 
agents has been performed (compound 10 MIC = 0.25 µg/mL against MRSA). Molecular modelling 
indicates rapid aggregation of this class of antibacterial agent prior to membrane association and 
insertion. Two fluorescent analogues (compound 29 with 4-amino-naphthalimide and 34 with 4-
nitrobenz-2-oxa-1,3-diazole fluorophores) with good activity (MIC = 0.5 µg/mL against MRSA) were 
also constructed and confocal microscopy studies indicate that the primary site of interaction for this 
family of compounds is the bacterial membrane. 
Keywords 
Antimicrobial, antibacterial, amphiphilic, fluorescence, naphthalimide, norbornane and microscopy 
1. Introduction 
There exists an urgent need to combat the emergence of multi-drug resistant (MDR) bacteria.[1-7] 
Positive steps have been taken to resolve the problem of bacterial resistance, and this issue has 
received significant media attention and high-priority recognition by leading health organisations 
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including WHO, British Health and the IDSA.[5] A number of initiatives have been aimed at enticing 
pharmaceutical companies to re-establish antibacterial product development.[8] Nevertheless, the 
inevitability of bacterial resistance to any newly approved drug reinforces the need to have new 
classes of antibacterial agents in the development pipeline; and particularly new drugs that limit the 
potential for bacterial resistance.[9, 10] 
Cationic antimicrobial peptides (CAMPs) are naturally occurring compounds that exhibit activity 
against most microbes including bacteria.[11, 12] The ability of CAMPs to adopt or be preorganised 
in a structurally amphiphilic manner, allows them to interact and ultimately perturb the bacterial 
membrane.[13, 14] Given their longstanding success in nature, it is widely thought that the 
development of bacterial resistance to these agents should be limited.[15, 16] The synthesis of 
peptidomimetics that also possess well-defined amphiphilic structure is therefore a logical step in the 
pursuit of new antibacterial agents and a number of research groups are currently active in this 
field.[17-20] 
The rigid norbornane scaffold has previously been used to prepare preorganised anion hosts[21, 22] 
and in turn facially amphiphilic cationic peptidomimetics,[23-25] including bisethers (such as 1, 
Figure 1)[24] and norbornane acetals (such as 2),[23] with both classes active against Gram-positive 
and Gram-negative bacterial strains. The acetal family were the more potent with structure-activity 
relationship (SAR) studies indicating that a dicationic charge and a long hydrophobic component were 
essential for activity.[23]   
 
Figure 1: Previously reported norbornane-based antibacterial agents.[23, 24] 
In order to further probe the SAR of these compounds, we envisaged analogues of bisguanidinium 2 
where the guanidine groups were further modified with, for example, a hydrophobic group. While a 
bisphenylguanidine norbornane has been previously reported,[25] the isolation of this product proved 
troublesome and as such we sought to devise a simpler and more robust synthetic route. 
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While it was originally hypothesised that the mode of action (MOA) of this norbornane class of 
compounds involved the membrane as the primary target, no experiments have been performed to 
establish this fact. Moreover, although the majority of CAMPs are membrane active there are many 
examples in which these peptides also have an intracellular target.[26] A combination of cellular 
targets is thought to lead to greater antibacterial activity as well as increasing the barrier to evolved 
resistance.[26] 
Fluorescence microscopy has been used to help elucidate antibacterial MOA of several 
peptidomimetic compounds,[27, 28] and compounds that aren’t inherently fluorescent can often be 
tagged with a small organic fluorophore with little impact on biological activity.[29] A plethora of 
small organic fluorescent compounds are available—including the 4-amino-1,8-naphthalimide[30] 
and 4-nitrobenz-2-oxa-1,3-diazole (NBD) fluorophores[31]—and these have been successfully used 
to provide an insight into important biological processes.  Both of these fluorophores exhibit large 
Stokes shifts, high quantum yields and typically emit in the green portion of the UV-visible spectrum 
(495–570 nm).[32, 33] 
This study outlines the synthesis and evaluation of six new norbornane-based antibacterial agents, 
including the most potent to date, and two fluorescent analogues that also possess excellent 
antibacterial activity.  A combination of molecular modelling and fluorescence microscopy has been 
used to provide an insight into the MOA of this class of compounds. 
2. Results and Discussion 
2.1. Chemistry 
Our preferred reagent for introducing the guanidine group was isothiourea 3[34, 35] and this 
compound was used here as the initial starting point to generate further functionalised guanidinylating 
agents. Unfortunately, the direct alkylation of 3 using NaH and BnBr gave 4 in poor yield. 
Neverthless, using Mitsunobu conditions (BnOH, PPh3, DIAD) benzylation was successful and 4 was 
isolated in excellent yield (95%, Scheme 1). Heating bisamines 5 and 8[23] with guanidinylating 
agent 4 and Et3N in CH2Cl2 gave the Boc-protected guanidines 6 and 9 respectively. The Boc-groups 
were then cleaved using methanolic HCl (generated from AcCl in MeOH) to give the desired 
guanidine hydrochloride salts 7 and 10. 
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Scheme 1: Reagents and conditions: (i) BnOH, DIAD, Ph3P, THF, 66 °C, 16 h, 95%; (ii) 4, Et3N, CH2Cl2, 40 °C, 2 d, 30%; 
(iii) AcCl, MeOH, 21 °C, 24 h, 93%; (iv) 4, Et3N, CH2Cl2, 80 °C, 2 d, 14%; (v) AcCl, MeOH, 21 °C, 24 h, 74%;  
It is known that the anion recognition group is important to the success of many antimicrobial 
peptides (AMPs) due to their ability to interact with negatively charged phosphates on the outer 
bacterial membrane.[36-38] To date, we have investigated a number of different anion recognition 
groups with varying degrees of success.[23] A guanidiniocarbonylpyrrole (GCP, 11) moiety has been 
reported by the Schmuck group[39] and has been shown to interact with anions that are part of large 
biological macromolecules.[40-42] In light of this work, we furnished bisamine 5 with the GCP group 
over two steps to give acyl guanidinium 13 (Scheme 2).   
 
Scheme 2: Reagents and conditions: (i) 11, PyBOP, DMAP, DMF, 80 °C, 16 h, 42%; (ii) AcCl, MeOH, 21 °C, 
24 h, 99%. 
In order to further functionalise the hydrophobic component of the norbornane acetals, N-Boc-
protected dodecanal 16 was desired. The synthesis of aldehyde 16 has been previously reported by 
Zeiler and co-workers where the oxidation of 14 was achieved using Swern conditions in 73% 
yield.[43] Unfortunately in our hands, and despite altering reaction conditions, including the amount 
of oxalyl chloride, temperature and reaction duration, aldehyde 16 could only be isolated in a 35% 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
yield after chromatographic purification (Error! Reference source not found., entries 1–3). 
Additional studies using 1H NMR indicated that aldehyde 16 degraded quickly; with the resonance 
assigned to the aldehyde (δ = 9.76 ppm) decreasing in size and relative integration over time. As such, 
another approach that could generate 16 rapidly, in high yields and without the need for a laborious 
column chromatography step was pursued.  
Table 1: Optimised synthesis of aldehyde 16. 
 
Entry S.M.a Redox agent 
(equiv.) 
Temp. 
(°C) 
Time 
(h) 
Yield 
(%) 
1b 14 (COCl2)2 (1.2)c 21 24 35 
2 14 (COCl2)2 (1.2)c −78 4 18 
3 14 (COCl2)2 (2.4)c −78 3 20 
4 14 PCC (1.5) 21 3 6 
5 14 PCC (3.0) 21 3 79 
6 14 TEMPO (0.2) 21 48 58 
7 15 LiAlH4 (1.5) −78 2 95 
a
 S.M. = starting material. 
b
 Stirred at −78 °C for 3 h before warming to 21 °C and stirred for a further 21 h. 
c
 DMSO (5.0 equiv.) used. 
Pyridinium chlorochromate (PCC) has been used extensively for the oxidation of primary alcohols to 
aldehydes.[44-46] Initially following the procedure described by Sanders and co-workers,[47] treating 
alcohol 14 with PCC (1.5 equiv.) gave aldehyde 16 in poor yield (6%), again, after chromatographic 
purification (Error! Reference source not found., entry 4). However, using a larger excess of PCC 
(3.0 equiv.) the alcohol was consumed after 3 hours and 16 was isolated in 79% yield, but again 
chromatographic purification was required (Error! Reference source not found., entry 5). Oxidation 
of 14 using TEMPO (0.2 equiv.) and (diacetoxyiodo)benzene,[48] afforded aldehyde 16 in 58% yield 
after a column chromatography step (Error! Reference source not found., entry 6). By far the most 
successful approach was reduction of Weinreb amide 15 using LiAlH4, to give aldehyde 16 in 95% 
yield after only two hours and with no requirement for chromatographic purification (Error! 
Reference source not found., entry 7). Maintaining the reaction temperature at −78 °C prevented the 
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formation of side-products and spectroscopically pure 16 was isolated after a simple extractive work-
up. 
Freshly prepared aldehyde 16 was reacted with diol 17 using previously established methodology[23] 
to give acetal 18 in a 78% yield (Scheme 3). The attachment of two guanidinium groups to the 
norbornane scaffold, using freshly prepared 2-[2,3-Bis(tert-butoxycarbonyl)guanidino]ethylamine 
(22),[34] was carried out over three steps.[24] Briefly, hydrolysis of the methyl esters gave 
dicarboxylic acid 19 in 88% yield. Standard EDCI/HOBt coupling conditions were employed to 
attach two units of 22 to the norbornane scaffold. Global deprotection using methanolic HCl gave the 
desired product 21 as the trihydrochloride salt. 
OR
OR
O
O
O
O
8
BocHN
i
OMe
OMe
O
O
HO
HO
17 18 R = Me
19 R = H
ii
N
H
NH
O
O
O
O
8
R'HN
20 R, R' = Boc
21 R = H, R' = H HCl
iv
H
N NR
NHR'
H
N NR
NHR'
iiiH2N
H
N
NHBoc
NBoc
22
 
Scheme 3: (i) 16, TsOH·H2O, MgSO4, PhMe, 110 °C, 3 h, 78%; (ii) NaOH, THF/H2O, 21 °C, 16 h, 88%; (iii) 22, EDCI, 
HOBt, CHCl3, 50 °C, 30 min, 32%; (iv) AcCl, MeOH, 21 °C, 2 d, 99%. 
In order to attach a fluorescent tag to the norbornane framework, Boc-protected amine 18 was 
deprotected to give amine 23 using the same methanolic HCl procedure described earlier. 
Condensation between amine 23 and 4-bromo-1,8-naphthalic anhydride 24 afforded the 
corresponding 4-bromo-1,8-naphthalimide 25 in near-quantitative yield (99%, Scheme 4). It should be 
noted that a trace amount of starting material 24 remained (as evidenced by 1H NMR spectroscopy) 
but this was eventually removed using column chromatography in the next step. While amination of 
the 4-bromo position of naphthalimides can be achieved using thermal SNAr conditions, concomitant 
amide formation could also occur at the methyl ester sites. As such, the method reported by Fleming 
and co-workers was followed to convert bromide 25 to the fluorescent 4-aminopropyl-1,8-
naphthalimide using propylamine, in the presence of Pd2(dba)3·CHCl3, xantphos and Cs2CO3 
(3.0 equiv.) in PhCH3 at 70 °C.[49] After chromatographic purification, fluorescent norbornane 26 
was isolated in excellent yield (88%). The attachment of two guanidinium groups to the norbornane 
scaffold was achieved over three steps, following the previously described methodology, to give 
naphthalimide 29 (Scheme 4). 
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Scheme 4: Reagents and conditions: (i) Et3N, EtOH, MW: 100 °C, 45 min, 99%; (ii) Propylamine, Pd2(dba)3·CHCl3, 
Xantphos, Cs2CO3, PhMe, 70 °C, 24 h, 88%; (iii) NaOH, THF/H2O, 21 °C, 16 h, 88%; (iv) 22, EDCI, HOBt, DMF, 21 °C, 2 
d, 82%; (v) AcCl, MeOH, 21 °C, 2 d, 97%. 
A similar protocol was used to construct the NBD analogue (Scheme 5). Aromatic substitution of 
commercially available NBC-Cl (30) with amine 23 proceeded smoothly to give the NBD-norbornane 
conjugate (31). After hydrolysis, amide coupling and Boc-deprotection, the desired NBD analogue 
(34) was isolated as the dihydrochloride salt. 
 
Scheme 5: Reagents and conditions: (i) Et3N, MeOH, 21 °C, 24 h, 68%; (ii) NaOH, THF/H2O, 21 °C, 16 h, 78%; (iii) 22, 
EDCI, HOBt, DMF, 21 °C, 3 d, 65%; (iv) AcCl, MeOH, 21 °C, 2 d, 95%. 
 
2.2. Photophysical properties 
All fluorescent analogues displayed properties typical of their respective fluorophores. Naphthalimide 
derivatives 28 and 29 exhibited absorption maxima at ~440 nm (Table 2) with corresponding 
emission maxima of ~530 nm in DMSO and 549 nm in H2O with Stokes shifts in the range of 84–
100 nm. Quantum yields for 28 and 29 in DMSO were high (0.89 and 0.88, respectively) whereas the 
quantum yield for 29 in H2O was significantly reduced (Φf = 0.16). Similarly, the NBD analogues 
also displayed characteristic fluorescent behaviour in DMSO (λabs ~ 475 nm, λex = 538 nm, Φf = 0.55). 
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In H2O a slight bathochromic shift in emission and decreased quantum yield was observed (λex = 550 
nm, Φf = 0.02).  Nonetheless, the properties observed for 29 and 34 in H2O were amenable for 
fluorescence microscopy. 
Table 2: Photophysical properties 
Compound Solvent λabs 
(nm) 
λem 
(nm) 
Stokes 
shift 
(nm) 
Φf 
28 DMSO 442 526 84 0.89 
29 DMSO 437 528 91 0.88 
29 H2O 449 549 100 0.16 
33 DMSO 475 538 63 0.55 
34 DMSO 472 538 66 0.55 
34 H2O 475 550 75 0.02 
  
2.3. Antimicrobial activity 
The six new compounds were evaluated against a range of Gram-negative and Gram-positive bacteria. 
The principal means of assessing activity was by broth-micro dilution (BMD) assay, to ascertain the 
minimum inhibitory concentration (MIC), of each compound.  For some analogues, disk diffusion 
assay (Kirby-Bauer), was also performed (see ESI for results). The new compounds exhibited 
excellent activity against a range of Gram-positive bacterial strains with MIC values comparable to 
Vancomycin (Table 3). The analogues containing the benzyl substituted guanidine groups (7, and 10) 
were the most active, with MIC values as low as 0.25 µg/mL; an improvement in activity compared to 
their previously synthesised non-substituted counterparts (no activity observed and one MIC value of 
1 µg/mL, respectively).[23] The tricationic analogue (21) only showed moderate activity (MIC = 8–16 
µg/mL) despite the presence of an extra charged moiety; reinforcing the notion that structural 
amphiphilicity is required for antibacterial activity. Importantly, both naphthalimide 29 and NBD 34 
were active (MIC value for both = 1 µg/mL against MRSA); comparable to the previously reported 
non-fluorescent norbornane 2 (MIC value of 2 µg/mL against MRSA).[23] This result suggests that 
the attachment of the largely hydrophobic fluorescent tag has minimal impact on the antibacterial 
activity of these compounds. Unfortunately, the GCP analogue (13) failed to show any activity at all. 
When these compounds were evaluated against Gram-negative bacterial strains only moderate or 
weak activity was noted, the best result was obtained for benzylguanidine 7 and NBD 34; both with 
MIC values of 8 µg/mL against Escherichia coli (Table 3). Given that a number of groups have 
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previously demonstrated the antifungal properties of CAMPs,[50, 51] compounds 7, 29 and 34 were 
also evaluated against pathogenic fungal strains (Table S3). All compounds exhibited activity, 
highlighted by an MIC of 0.25 µg/mL for naphthalimide 29 against Cryptococcus neoformans; 
considerably more potent than the clinically used antifungal agent Fluconazole (MIC = 8 µg/mL, 
Table S3). 
Table 3: MIC values (µg/mL) 
Bacterial strain 7 10 13 21 29 34 COLa VANb 
A. baumannii ATCC 19606 >32 >128 >128 >32 >32 32 0.06 NTc 
P. aeruginosa ATCC 27853 32 >128 >128 >32 >32 32 0.25 NT 
K. pneumoniae ATCC 700603 >32 >128 >128 >32 >32 >32 0.03 NT 
E. coli ATCC 25922 8 >128 >128 >32 >32 8 0.06 NT 
S. aureus ATCC 43300 2 0.25 >128 16 1 1 NT 1 
S. aureus NARSA NRS17 1 0.25 >128 16 4 1 NT 4 
S. aureus NARSA NRS1 2 0.5 >128 8 4 4 NT 4 
S. aureus NARSA VRS 10 1 0.5 128 8 2 0.5 NT >64 
S. pneumoniae ATCC 7000677 2 1 >128 8 1 1 NT 1 
a COL = Colistin sulphate. 
b
 VAN = Vancomycin 
c NT = Not tested. 
The cytotoxicity of most compounds when tested against human embryonic kidney cells (HEK293, 
Table 4) was modest, with CC50 values >50 µg/mL. While the highly active benzylguanidine 10 did 
show considerable toxicity the CC50 was still an order of magnitude above its MIC. Pleasingly, 
benzylgaunidine 7 and fluorescent analogues 29 and 34, each of which exhibited excellent 
antibacterial activity against Gram-positive bacteria (MIC 1, 2 and 0.5 µg/mL respectively), showed 
CC50 values >50 µg/mL.   
Table 4: Cytotoxicity (CC50) against HEK293 cells (µg/mL) 
 7 10 13 21 29 34 TAMa 
CC50 >50 7.8 >100 >50 >50 >50 13 
a TAM = Tamoxifen 
 
2.4 Molecular modelling 
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Molecular dynamics simulations were performed to identify potential interactions between the 
compounds and a model of a cell membrane from Gram-negative bacteria (see experimental for 
details regarding model membrane construction). The Gram-positive cell wall is comprised of a thick 
peptidoglycan layer whilst Gram-negative bacteria have a comparatively thin peptidoglycan layer 
within their cellular envelope (up to 90% versus 10%, respectively).[52, 53] Molecular modelling that 
incorporates peptidoglycans presents a significant challenge as the complete assembled structure of 
peptidoglycans is not yet fully understood.[54] As such, a Gram-negative bacterial cell membrane was 
chosen for this study to circumvent complications associated with peptidoglycans. The compounds 
modelled included the previously reported norbornanes bisguanidine (2) and bisamine (8)[23] as well 
as naphthalimide (29) and benzylguanidine (7). Two sets of simulations were performed; one set to 
determine if these compounds self-aggregate, and the second set to determine how they interact with 
the model bacterial cell wall.  
Self-association was readily apparent and all compounds were found to aggregate to form clusters 
(Figure 2), a logical outcome given the amphiphilic nature of the compounds. The aggregation 
occurred relatively quickly, on the sub-microsecond timescale, and as such it is likely that, in vivo, a 
level of aggregation occurs prior to insertion into the lipid bilayer. Dimerisation, and even 
oligomerisation, to form the active antibacterial agent, is a feature of a number of antibiotics including 
Vancomycin,[55] Daptomycin[56] and a variety of cationic antimicrobial peptidomimetics.[57]  
 
Figure 2: A snapshot of the assembled ten molecule aggregates. Yellow, cyan, orange and purple represent the 
carbon atoms of the bisamine (8), bisguanidine (2), benzylguanidine (7) and naphthalimide (29) species 
respectively. Nitrogen is coloured blue, oxygen = red, hydrogen = white). Water molecules and Cl- have been 
omitted for clarity. 
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Additional computational studies were performed on bisguanidine (2), chosen as a representative 
example, to probe how this class of compounds interacts with bacterial cell membranes. An aggregate 
consisting of 28 molecules of 2 (see experimental section for the construction of this aggregate) was 
inserted into the aqueous (extracellular) portion of a Gram-negative bacterial inner membrane model 
(Figure 3, LHS). The 228 aggregate was partially absorbed into the membrane in each of the three 
replicate simulations and full absorption was expected were the simulations to be continued. The 
incorporation of the 228 aggregate into the membrane occurred in a series of steps. First, the aggregate 
contacted the membrane. The aggregate stayed attached at the same position of the membrane due to 
strong electrostatic interactions between the positively charged 228 aggregate and the negatively 
charged lipid molecules (DMPG). The aggregate maintained its integrity for a few hundred 
nanoseconds until individual molecules of 2 were drawn into the membrane (Figure 3, Centre). The 
aggregate then slowly broke down with additional individual molecules diffusing into the membrane 
(Figure 3, RHS).  While no distinct pore formation was observed, some water molecules did penetrate 
into the membrane (see video in supplementary material). These water molecules appeared to be 
stabilised inside the membrane by interactions with the charged guanidine moieties of 2. In one 
replicate a significant amount of membrane curvature was evident when the intact aggregate contacted 
the membrane (see Figure S50). In all three replicates the interaction between the 228 aggregate and 
the model membrane followed an identical pattern that indicates this class of compound aggregates 
quickly in vivo prior to inserting into to the membrane, before slowly breaking apart. This series of 
events would likely decrease membrane stability, increase membrane permeability and ultimately lead 
to cell lysis—a known mode of action for CAMPs and mimics such as Colistin.[37] 
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Figure 3: Simulation snapshots highlighting the insertion/absorption of bisguanidine aggregate (228) into a model 
membrane. LHS: Simulation begins with the aggregate deliberately positioned in the “extracellular 
environment” above the model membrane. Centre: membrane contact established and lipid absorption 
underway. RHS: simulation end with aggregate embedded in the membrane and some dispersion evident. Lipid 
molecules are coloured grey (PPoPE) and red (DMPG), 2 is coloured by element (carbon = cyan, nitrogen = 
blue, oxygen = red and hydrogen = white). Water molecules, Na+ and Cl- have been omitted for clarity. A video 
of the membrane insertion process is available in the electronic supplementary information. 
2.5 Fluorescence microscopy 
Confocal microscopy was performed to assess localisation of fluorescent compounds 29 and 34 in 
Gram-positive and Gram-negative bacteria. Two control fluorophores were also assessed, 
naphthalimide 35 and NBD 36 (Figure 4, see ESI for the full synthesis and characterisation of these 
controls).  
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Figure 4: (A) Structure of compounds used in microscopy studies: Norbornanes 29 and 34 plus controls 35 and 
36. (B–C) Localisation of compounds in bacteria. Confocal micrographs showing localisation of compounds in 
(B) S. aureus MRSA and (C) E. coli. Scale bar = 5 µm. (D) 3D rendering showing cell wall localisation of 
compound 29 in E. coli. Box dimensions x:y:z 5.4 µm:4.0 µm:2.3 µm. 
Bacteria were incubated for 20 minutes with 10 µg/mL of the fluorescent compound. In Gram-
positive S. aureus the staining pattern for both compounds 29 and 34 was similar with fluorescence 
observed throughout the cell but the intensity was greatest at the cell periphery (Figure 4B). 
Naphthalimide 35 localised throughout the cell and NBD 36 localised to the cell periphery; similar to 
norbornane compounds 29 and 34, however the overall fluorescence was considerably less intense for 
the control compounds 35 and 36. This decreased intensity is likely a result of weaker interactions 
with the bacterial membrane as both control compounds 35 and 36 lack the guanidine groups that act 
as anion recognition moieties targeting the phosphate groups present in the bacterial outer membrane.  
When Gram-negative E. coli was incubated with 29 and 34, a similar distribution within the cells was 
observed (Figure 4C). Once again, greater localisation occurred at the cell periphery, with distinct 
regions of higher concentration particularly evident when three dimensional images were taken 
(Figure 4D, also see ESI for associated video). The simple organic fluorophores used as controls (35 
and 36) occasionally localised to similar regions, but with less consistency and intensity, than 
compounds 29 and 34, again highlighting the role of the positively charged groups present on the 
norbornane-based compounds for cell wall interactions. 
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The use of molecular modelling and fluorescence microscopy indicate that this class of antibacterial 
agent likely aggregates rapidly prior to interacting with the bacterial cell membrane. Both the 
modelling outcomes and the fluorescence microscopy studies using naphthalimide 29 and NBD 34 
clearly show the norbornane-based compounds localised on the bacterial membrane highlighting the 
important role of the cationic groups. Fluorescence microscopy experiments showed that 
naphthalimide 29 interacts with the membrane for both S. aureus and E. coli, however cell penetration 
was only observed in S. aureus; a potential cause for the increased antibacterial activity demonstrated 
by these compounds against Gram-positive bacterial species. Indeed, many AMPs such as the 
bacteriocin family, which includes colicins and lantibiotics,[58] demonstrate strain-specific 
antibacterial activity, despite relying on a mode of action that primarily involves membrane 
interactions as the first step.[59, 60] With this in mind and comparing the outcomes to those of 
CAMPs in the literature,[61, 62] it is suggested that these compounds function as mimetics of cationic 
antimicrobial peptides. 
 
3. Conclusions 
In summary, a series of norbornane-based CAMP mimics were synthesised—two dibenzylguanidine 
substituted (7 and 10), one guanidiniocarbonylpyrrole-functionalised (13), one tricationic (21) and 
two fluorescently tagged, using the 4-amino naphthalimide and NBD fluorophores (29 and 34, 
respectively). Incorporation of the dibenzylguanidine groups enhanced the antibacterial activity of the 
compounds, albeit in the case of 10 some cytotoxicity was observed. The importance of retaining a 
structurally amphiphilic topology was reinforced as non-amphiphilic tricationic analogue 21 was 
considerably less active than its amphiphilic diatonic counterparts. Antibacterial activity of the 
fluorescent analogues was comparable to the previously described norbornane acetal 2 with each 
compound active against several strains of Gram-positive bacteria (MIC values as low as 0.5 µg/mL). 
Additionally, NBD 34 exhibited activity against several Gram-negative bacterial strains. This 
structurally amphiphilic class of low-molecular weight CAMP mimics are readily synthesised and 
possess promising antimicrobial activity.  
 
4. Experimental 
4.1. Chemistry 
The following compounds and their respective precursors were prepared using literature methods and 
full reaction details can be found in the supplementary information; 3,[34] 5,[23] 8,[23] 14,[63] 
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17,[24] 22,[35] 35[64, 65] and 36.[66] Compound 11 was kindly donated by the Schmuck research 
group and its synthesis has been previously reported.[39] 
4.1.1. N,Nʹ-Bis(tert-butoxycarbonyl)-N-benzyl-S-methylisothiourea (4).[67]  
To a stirring solution of methylisothiourea 3 (1.04 g, 3.58 mmol) in anhydrous THF (12.8 mL) at 
ambient temperature under an inert atmosphere, was added Ph3P (1.50 g, 5.73 mmol) followed by 
BnOH (490 µL, 4.65 mmol). The homogenous solution was cooled to 0 °C, before Diisopropyl 
azodicarboxylate (DIAD, 1.1 mL, 5.37 mmol) was added slowly. The yellow solution was warmed to 
ambient temperature and then heated to 66 °C for 16 h. The reaction mixture was concentrated under 
reduced pressure and the crude material was diluted with H2O (10 mL) and extracted with CH2Cl2 (3 
× 15 mL). The combined organic phases were washed with brine (10 mL), dried (MgSO4), filtered 
and concentrated in vacuo to give a yellow oil which was stirred in pet. spirits (20 mL) at ambient 
temperature for 1 h. The resulting white precipitate was collected using vacuum filtration and 
discarded. The remaining filtrate was purified using column chromatography (10% EtOAc in pet. 
spirits) to give a light green oil (1.29 g, 95%). Rf = 0.38 (10% EtOAc in pet. spirits). 1H NMR (270 
MHz, CDCl3) δ 7.36–7.24 (5H, m, ArH), 4.78 (2H, s, CH2), 2.28 (3H, s, CH3), 1.52 (9H, s, t-Bu), 1.39 
(9H, s, t-Bu). 13C NMR (67.5 MHz, CDCl3) δ 163.3, 158.1, 152.1, 137.5, 128.7, 128.5, 127.8, 127.6, 
127.4, 82.8, 81.9, 52.6, 28.2, 28.1, 15.7. HRMS (ESI, m/z) for C19H28N2O4S [M + Na]+ calc. 
403.1662; found 403.1664. 
4.1.2. tert-Butyl-[12-(methoxy[methyl]amino)-12-oxododecyl]carbamate (15).  
A mixture of carboxylic acid 40 (5.46 g, 17.30 mmol), 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDCI, 4.02 g, 20.94 mmol), 1-hydroxybenzotriazole (HOBt, 
241 mg, 1.78 mmol), N,O-dimethylhydroxylamine hydrochloride (2.05 g, 20.97 mmol), CHCl3 (80 
mL) and N,N-diisopropylethylamine (DIPEA, 15.4 mL, 86.5 mmol) was stirred at 65 °C for 24 h. The 
reaction was cooled to ambient temperature and the mixture was washed with 0.1 M HCl (40 mL), 
sat. NaHCO3 (40 mL), brine (40 mL), then dried (MgSO4), filtered and concentrated in vacuo. The 
crude material was purified using column chromatography (20–50% EtOAc in pet. spirits) to afford 
the title compound (5.40 g, 87%) as a colourless viscous oil. Rf = 0.56 (50% EtOAc in pet. spirits). 1H 
NMR (400 MHz, CD l3) δ 4.51 (1H, br s, NH), 3.67 (3H, s, OCH3), 3.17 (3H, s, NCH3), 3.09–3.08 
(2H, m, NHCH2), 2.40 (2H, t, J = 7.5 Hz, CH2CO), 1.65–1.57 (2H, m, CH2), 1.46–1.39 (9H, m, t-Bu), 
1.29–1.26 (16H, m, 8 × CH2). 13C NMR (100 MHz, CDCl3) δ 174.9, 156.1, 79.2, 61.3, 40.8, 32.3, 
32.0, 30.2, 29.64, 29.63, 29.58, 29.57, 29.5, 29.4, 28.6, 26.9, 24.8. HRMS (ESI, m/z) for C19H38N2O4 
[M + H]+ calc. 359.2904; found 359.2904. 
4.1.3. N-(tert-Butoxycarbonyl)-12-aminododecanal (16).  
Method A[43] 
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To the stirring solution of oxalyl chloride (140 µL, 1.60 mmol) in anhydrous CH2Cl2 (8 mL) at −78 
°C, was added DMSO (230 µL, 3.19 mmol), alcohol 14 (400 mg, 1.33 mmol) in anhydrous CH2Cl2 
(1.5 mL) and Et3N (1 mL, 7.18 mmol) successively. Stirring was maintained under an inert 
atmosphere at −78 °C for 3 h before being warmed to ambient temperature and stirred for a further 16 
h. The reaction was diluted with H2O (20 mL) and extracted with Et2O (2 × 20 mL). The combined 
organic phase was washed with brine (20 mL), dried (MgSO4), filtered and concentrated in vacuo. 
The crude material was purified using column chromatography (10% EtOAc in pet. spirits) to give the 
title compound (140 mg, 35%) as a white solid. 
Method B[47] 
Alcohol 14 (1.04 g, 3.43 mmol) was added to a stirring mixture of neutral alumina (5.09 g, 
50.0 mmol) and pyridinium chlorochromate (PCC, 2.18 g, 10.1 mmol) in CH2Cl2 (33 mL) and stirring 
was maintained at ambient temperature for 3 h. The solid material was removed by filtration (rinsing 
with CH2Cl2) and the filtrate was concentrated in vacuo. The crude material was purified using 
column chromatography (20% EtOAc in pet. spirits) to give the product (808 mg, 79%) as a white 
solid. 
Method C[48] 
Alcohol 14 (209 mg, 0.693 mmol) was stirred in CH2Cl2 (1.4 mL) at ambient temperature before 
(2,2,6,6-tetramethylpiperidin-1-yl)oxyl (TEMPO, 13 mg, 0.083 mmol) and (diacetoxyiodo)benzene 
(246 mg, 0.762 mmol) were added. The pale orange solution was stirred at ambient temperature for a 
further for 24 h before more TEMPO (13 mg, 0.083 mmol) was added. Stirring was maintained for 
another 24 h and the reaction was then quenched with sat. Na2SO3 (8 mL) and extracted with CH2Cl2 
(3 × 5 mL). The combined organic phase was washed with sat. NaHCO3 (5 mL), brine (5 mL), dried 
(MgSO4), filtered and concentrated in vacuo. The crude material was purified using column 
chromatography (20% EtOAc in pet. spirits) to give the title compound (112 mg, 58%) as a white 
solid.  
Method D[68] 
A stirring solution of Weinreb amide 15 (994 mg, 2.77 mmol) in anhydrous THF (30 mL) was added 
LiAlH4 (4.2 mL, 4.16 mmol, 1 M solution in Et2O), at −78 °C under an inert atmosphere. Stirring was 
maintained for 2 h before the reaction was quenched with 1 M HCl (20 mL) and extracted with 
CH2Cl2 (3 × 30 mL). The combined organic phase was washed with brine (30 mL), dried (MgSO4), 
filtered and concentrated in vacuo to give a white solid (790 mg, 95%) that did not require further 
purification. Rf = 0.45 (20% EtOAc in pet. spirits). m.p. 51–53 °C (lit. 51 °C).[43] 1H NMR (500 
MHz, CDCl3) δ 9.76 (1H, t, J = 1.8 Hz, CHO), 4.48 (1H, br s, NH), 3.09 (2H, t, J = 7.0 Hz, 
CH2NHBoc), 2.41 (2H, dt, J = 7.4, 1.8 Hz, CH2CHO), 1.65–1.59 (2H, m, CH2), 1.47–1.44 (11H, m, 
CH2, t-Bu), 1.29–1.26 (14H, m, 7 × CH2). 13C NMR (125 MHz, CDCl3) δ 203.1, 156.2, 79.2, 44.1, 
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40.8, 30.2, 29.63, 29.60, 29.51, 29.46, 29.4, 29.3, 28.6, 26.9, 22.2. HRMS (ESI, m/z) for C17H33NO3 
[M + Na]+ calc. 322.2353; found 322.2353.  
4.1.4. 8-endo-9-exo-Di[2ʹ-(2ʺ,3ʺ-bis-tert-butoxycarbonyl-3ʺ-benzylguanidino)ethylcarbamoyl]-4-
heptyl-3,5-dioxatricyclo[5.2.1.02,6]decane (6).  
A mixture of diamine 5 (80 mg, 0.165 mmol) and Et3N (60 µL, 0.41 mmol) in CH2Cl2 (300 µL) was 
stirred for 30 min at ambient temperature before a solution of methylisothiourea 510 (130 mg, 
0.341 mmol) in CH2Cl2 (900 µL) was added in one portion and the reaction was heated to 40 °C for 
2 d. The reaction mixture was diluted with CH2Cl2 (10 mL), transferred to a separatory funnel and 
washed with H2O (2 × 5 mL), brine (5 mL), dried (MgSO4) and filtered. The solvent was removed in 
vacuo and the crude material was purified using flash column chromatography (20–70% EtOAc in 
pet. spirits) to give the title compound (53 mg, 30%) as a colourless viscous oil. Rf = 0.46 (70% 
EtOAc in pet spirits). 1H NMR (500 MHz, CDCl3) δ 7.33–7.27 (10H, m, ArH), 4.79 (4H, br s, 
ArCH2), 4.52 (1H, br s, H4), 4.10 (1H, br s, H6), 3.92 (1H, d, J = 5.5 Hz, H2), 3.33–3.21 (8H, m, 4 × 
NHCH2), 2.87 (1H, app. t, J = 5.1 Hz, H8), 2.61 (1H, br s, H9), 2.57 (1H, br s, H7), 2.32 (1H, d, J = 
5.9 Hz, H1), 1.76 (1H, d, J = 9.9 Hz, H10a), 1.61–1.25 (49H, m, 6 × CH2, 4 × t-Bu, H10s), 0.87 (3H, 
t, J = 6.8 Hz, CH3). 13C NMR (125 MHz, CDCl3) δ 174.3, 172.6, 153.5 (2 × C), 138.0, 137.8, 128.7 (6 
× C), 128.3, 128.2, 128.0, 127.8, 104.0, 83.3, 83.1, 81.5, 79.7 (2 × C), 78.7, 51.4, 51.3, 47.8, 44.6, 
44.3, 43.2, 43.0, 39.6, 38.8, 33.0, 32.5, 31.9, 29.8, 29.6, 29.3, 28.33, 28.32, 28.21, 28.17, 24.3, 22.7, 
14.2. HRMS (ESI, m/z) for C57H84N8O12 [M + H]+ calc. 1075.6438; found 1075.6429. 
4.1.5. 4-Heptyl-3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-di[carboxamidoethyl-(3ʺ-
benzyl)guanidine] hydrogen chloride (7). 
To a stirring solution of Boc-protected guanidine 6 (40 mg, 0.04 mmol) and MeOH (370 µL) was 
added dropwise AcCl (70 µL, 0.987 mmol), and the reaction was stirred for 24 h at ambient 
temperature. The reaction was concentrated in vacuo and co-evaporated with MeOH (2 × 0.5 mL), to 
afford the title compound (25 mg, 93%) as a white solid. 1H NMR (270 MHz, CD3OD) δ 7.40–7.30 
(10H, m, ArH), 4.61 (1H, t, J = 4.6 Hz, H4), 4.42–4.41 (4H, m, 2 × ArCH2), 4.03 (1H, d, J = 5.4 Hz, 
H2), 3.98 (1H, d, J = 5.4 Hz, H6), 3.41–3.34 (8H, m, 4 × NHCH2), 3.21 (1H, app. t, J = 4.8 Hz, H8), 
2.62–2.61 (2H, m, H1, H7), 2.45 (1H, br s, H9), 1.72 (1H, d, J = 10.2 Hz, H10a), 1.60–1.56 (2H, m, 
CH2), 1.45 (1H, d, J = 10.2 Hz, H10s), 1.39–1.29 (10H, m, 5 × CH2), 0.89 (3H, t, J = 6.8 Hz, CH3). 
13C NMR (67.5 MHz, CD3OD) δ 176.7, 174.7, 157.7 (2 × C), 129.9 (4 × C), 129.0 (4 × C), 128.5 (2 × 
C), 128.4 (2 × C), 105.1, 82.8, 79.9, 47.7, 47.0, 46.2, 46.1, 45.1, 44.9, 42.4 (2 × C), 39.7, 39.6, 33.9, 
32.9, 32.7, 30.6, 30.3, 25.2, 23.7, 14.4. HRMS (ESI, m/z) for C37H54N8O4 [M + 2H]2+ calc. 338.2207; 
found 338.2208. 
4.1.6. 8-endo-9-exo-Di[2ʹ-(2ʺ,3ʺ-bis-tert-butoxycarbonyl-3ʺ-benzylguanidino)ethylcarbamoyl]-4-
pentadecyl-3,5-dioxatricyclo[5.2.1.02,6]decane (9).  
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A mixture of diamine 8 (284 mg, 0.476 mmol) and Et3N (30 µL, 0.21 mmol) in CH2Cl2 (2.5 mL) was 
stirred for 30 min at ambient temperature in a pressure vessel, before a solution of methylisothiourea 4 
(431 mg, 1.13 mmol) in CH2Cl2 (2.5 mL) was added in one portion and the reaction was heated to 
80 °C for 2 d. The reaction mixture was diluted with CH2Cl2 (10 mL), transferred to a separatory 
funnel and washed with H2O (2 × 10 mL), brine (10 mL), dried (MgSO4) and filtered. The solvent 
was removed in vacuo and the crude material was purified using flash column chromatography (50–
70% EtOAc in pet. spirits) to give the title compound (83 mg, 14%) as a colourless viscous oil. Rf = 
0.65 (70% EtOAc in pet spirits). 1H NMR (270 MHz, CDCl3) δ 7.35–7.26 (10H, m, ArH), 4.78 (4H, 
br s, ArCH2), 4.52 (1H, br s, H4), 4.10 (1H, d, J = 9.8 Hz, H6), 3.92 (1H, d, J = 5.5 Hz, H2), 3.31–
3.14 (8H, m, 4 × NHCH2), 2.87 (1H, app. t, J = 5.1 Hz, H8), 2.61 (1H, br s, H9), 2.57 (1H, br s, H7), 
2.32 (1H, d, J = 5.8 Hz, H1), 1.75 (1H, d, J = 9.8 Hz, H10a), 1.61–1.25 (61H, m, 12 × CH2, 4 × t-Bu, 
H10s), 0.87 (3H, t, J = 7.0 Hz, CH3). 13C NMR (67.5 MHz, CDCl3) δ 174.3, 172.6, 153.4 (2 × C), 
138.0, 137.9, 128.7 (6 × C), 128.3 (2 × C), 127.8 (2 × C), 104.0, 83.3, 83.1, 81.5, 79.7, 78.8, 77.3, 
51.4, 51.3, 47.8, 44.7, 44.3, 43.2, 43.0, 39.7, 38.8, 33.0, 32.5, 32.0, 29.80, 29.77, 29.71, 29.67, 29.5, 
28.34 (3 × C), 28.32 (3 × C), 28.21, 28.17, 24.3, 22.8, 14.3.  
4.1.7. 4-Pentadecyl-3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-di[carboxamidoethyl-(3ʺ-
benzyl)guanidine] hydrogen chloride (10).  
To a stirring solution of Boc-protected guanidine 9 (101 mg, 0.085 mmol) and MeOH (5 mL) was 
added dropwise AcCl (250 µL, 3.52 mmol), and the reaction was stirred for 24 h at ambient 
temperature. The reaction was concentrated in vacuo and co-evaporated with MeOH (2 × 0.5 mL), to 
afford the title compound (54 mg, 74%) as a white solid. m.p. 174–180 °C (slow decomposition). 1H 
NMR (270 MHz, CD3OD) δ 7.38–7.31 (10H, m, ArH), 4.61 (1H, t, J = 4.6 Hz, H4), 4.47–4.41 (4H, 
m, 2 × ArCH2), 4.04 (1H, d, J = 5.6 Hz, H2), 3.98 (1H, d, J = 5.6 Hz, H6), 3.40–3.30 (8H, m, 4 × 
NHCH2), 3.21 (1H, app. t, J = 4.8 Hz, H8), 2.65–2.61 (2H, m, H1, H7), 2.46 (1H, br s, H9), 1.72 (1H, 
d, J = 10.2 Hz, H10a), 1.60–1.55 (2H, m, CH2), 1.45 (1H, d, J = 10.2 Hz, H10s), 1.36–1.22 (24H, m, 
12 × CH2), 0.90 (3H, t, J = 6.8 Hz, CH3). 13C NMR (67.5 MHz, CD3OD) δ 176.7, 174.7, 157.7 (2 × 
C), 137.6, 129.9 (3 × C), 129.0 (4 × C), 128.5 (2 × C), 128.4 (2 × C), 105.1, 82.8, 80.0, 47.7, 46.9, 
46.2, 46.1, 45.2, 44.9, 42.4 (2 × C), 39.7, 39.6, 33.9, 33.1, 32.7, 30.77, 30.75, 30.7 (2 × C), 30.64 (2 × 
C), 30.62, 30.5, 25.2, 23.7, 14.4. HRMS (ESI, m/z) for C45H70N8O4 [M + 2H]2+ calc. 394.2833; found 
394.2842. 
4.1.8. 8-endo-9-exo-Di[2ʹ-(5″-acetamido-1H-pyrrole-2″-N-tert-butoxycarbonyl-
guanidiniocarbonyl)ethylcarbamoyl]-4-heptyl-3,5-dioxatricyclo[5.2.1.02,6]decane (12).  
A solution of GCP 11 (104 mg, 0.116 mmol), (benzotriazol-1-yloxy)tripyrrolidinophosphonium 
hexafluorophosphate (PyBOP, 163 mg, 0.313 mmol), 4-(dimethylamino)pyridine (DMAP, 8 mg, 
0.07 mmol) and DMF (0.5 mL) was stirred at ambient temperature. To the homogenous yellow 
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solution was added Et3N (90 µL, 0.646 mmol) and the solution gradually turned to red and then 
eventually bright orange. To the stirred solution was added diamine 5 (56 mg, 0.116 mmol) and the 
biphasic mixture was stirred at 80 °C for 16 h. The reaction was quenched with H2O (2 mL) and the 
white precipitate was collected using vacuum filtration. The crude material was stirred in 10% pet. 
spirits in CH2Cl2 for 1 h, cooled and then collected using vacuum filtration to afford the desired 
product (47 mg, 42%) as an off-white solid. Rf = 0.41 (89% CH2Cl2, 10% MeOH, 1% NH4OH). m.p. 
217–252 °C (slow decomposition). 1H NMR (500 MHz, DMSO-d6) δ 11.30–10.88 (4H, br s, 4 × NH), 
9.34 (2H, br s, 2 × NH), 8.58 (2H, br s, 2 × NH), 8.40 (2H, br s, 2 × NH), 8.12–8.10 (2H, m, 2 × NH), 
6.80–6.75 (4H, m, 4 × CH), 4.44 (1H, t, J = 4.3 Hz, H4), 3.84 (1H, d, J = 5.6 Hz, H6), 3.79 (1H, d, J 
= 5.6 Hz, H2), 3.36–3.27 (8H, m, 4 × CH2), 3.14–3.09 (1H, m, H8), 2.50 (2H, m, H1, H7), 2.29 (1H, 
br s, H9), 1.45 (19H, br s, t-Bu, H10a), 1.21–1.08 (13H, m, 6 × CH2, H10s), 0.85 (3H, t, J = 6.6 Hz, 
CH3). 13C NMR (125 MHz, DMSO-d6) δ 173.1 (2 × C), 171.2 (2 × C), 159.8 (4 × C), 158.5 (2 × C), 
129.7 (2 × C), 113.7 (2 × C), 111.7 (2 × C), 111.6 (2 × C), 102.9, 81.0, 78.2, 46.3, 44.3, 43.2, 42.7, 
38.7 (2 × C), 38.4 (2 × C), 32.4, 31.2, 31.0, 29.0, 28.7, 27.8, 23.8, 22.1, 14.0.   
4.1.9. 4-Heptyl-3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-di[carboxamidoethyl-(5″-
acetamido-1H-pyrrole-2″)-guanidiniocarbonyl] hydrogen chloride (13).  
To a stirring solution of Boc-protected guanidine 12 (93 mg, 0.096 mmol) and MeOH (2 mL) was 
added dropwise AcCl (280 µL, 3.94 mmol), and the reaction was stirred for 24 h at ambient 
temperature. The reaction was concentrated in vacuo and co-evaporated with MeOH (2 × 0.5 mL), to 
afford the title compound (79 mg, 99%) as a brown solid. m.p. 206–209 °C. 1H NMR (500 MHz, 
DMSO-d6) δ 12.34–12.31 (2H, m, 2 × NH), 11.95–11.94 (2H, m, 2 × NH), 8.63–8.43 (8H, m, 8 × 
NH), 8.17–8.14 (2H, m, 2 × NH), 7.50 (2H, br s, 2 × CH), 6.84 (2H, br s, 2 × CH), 4.49 (1H, t, J = 
4.7 Hz, H4), 3.87 (1H, d, J = 4.9 Hz, H6), 3.82 (1H, d, J = 4.9 Hz, H2), 3.75–3.63 (2H, br s, 2 × NH), 
3.28–3.13 (8H, m, 4 × CH2), 3.09 (1H, app. t, J = 4.8 Hz, H8), 2.50 (2H, m, H1, H7), 2.30 (1H, br s, 
H9), 1.50–1.45 (3H, m, CH2, H10a), 1.28–1.10 (11H, m, 5 × CH2, H10s), 0.85 (3H, t, J = 6.8 Hz, 
CH3). 13C NMR (125 MHz, DMSO-d6) δ 173.1, 171.2, 159.6 (2 × C), 159.3 (2 × C), 155.4 (2 × C), 
132.90, 132.87, 125.4 (2 × C), 115.9 (2 × C), 112.4 (2 × C), 102.9, 81.0, 78.2, 46.3, 44.4, 43.2, 42.7, 
38.72, 38.71, 38.5, 38.3, 32.4, 31.2, 31.0, 28.9, 28.6, 23.8, 22.1, 14.0. HRMS (ESI, m/z) for 
C35H52N12O8 [M + 2H]2+ calc. 384.2010; found 384.2019. 
4.1.10. Dimethyl 4-[11ʹ-(tert-butoxycarbonylamino)undecyl]-3,5-dioxatricyclo[5.2.1.02,6]decane-
8-endo-9-exo-dicarboxylate (18). 
A stirring suspension of diol 17 (323 mg, 1.32 mmol), TsOH·H2O (13 mg, 0.07 mmol), MgSO4 
(166 mg, 1.38 mmol) and PhMe (2.2 mL) was treated with aldehyde 16 (587 mg, 1.96 mmol) and 
heated to 110 °C for 3 h. Solid MgSO4 was removed by filtration and the filtrate was diluted with 
EtOAc (20 mL), washed with H2O (2 × 10 mL), brine (10 mL), dried (MgSO4), filtered and 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
concentrated in vacuo. The crude material was purified using column chromatography (20% EtOAc in 
pet. spirits) to afford the title compound (542 mg, 78%) as a colourless oil. Rf = 0.44 (20% EtOAc in 
pet. spirits). 1H NMR (500 MHz, CDCl3) δ 4.65 (1H, t, J = 5.2 Hz, H4), 4.50 (1H, br s, NH), 4.02 
(1H, d, J = 5.6 Hz, H2), 3.89 (1H, d, J = 5.6 Hz, H6), 3.70–3.69 (6H, m, 2 × Me), 3.22 (1H, app. t, J = 
4.8 Hz, H8), 3.08 (2H, app. t, J = 7.0 Hz, CH2NHBoc), 2.71 (1H, d, J = 4.8 Hz, H9), 2.64–2.63 (2H, 
m, H1, H7), 1.77 (1H, dd, J = 10.9, 1.4 Hz, H10a), 1.64–1.60 (2H, m, CH2), 1.43 (9H, s, t-Bu), 1.39–
1.24 (19H, m, 9 × CH2, H10s). 13C NMR (125 MHz, CDCl3) δ 174.1, 172.9, 156.1, 104.3, 81.4, 79.1, 
78.9, 52.5, 52.3, 45.4, 45.1, 43.8, 43.4, 40.8, 32.9, 31.7, 30.2, 29.82, 29.78, 29.64, 29.59, 29.5, 29.4, 
28.6, 26.9, 24.3. HRMS (ESI, m/z) for C28H47NO8 [M + Na]+ calc. 548.3194; found 548.3171. 
4.1.11. 4-[11ʹ-(tert-butoxycarbonylamino)undecyl]-3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-9-
exo-dicarboxylic acid (19). 
To the stirred solution of the ester 18 (27 mg, 0.05 mmol) in THF (210 µL), 2M NaOH (110 µL) was 
added and the reaction was stirred for 16 h at ambient temperature. The reaction was concentrated 
under reduced pressure and all organic-soluble impurities were extracted with CH2Cl2 (2 × 5 mL). The 
aqueous solution was acidified with sat. KH2PO4 (pH = 5), extracted with EtOAc (3 × 8 mL), dried 
(MgSO4) and filtered to give a colourless oil (22 mg, 88%). 1H NMR (500 MHz, CDCl3) δ 4.68 (1H, 
t, J = 4.9 Hz, H4), 4.59 (1H, br s, NH), 4.04 (2H, s, H2, H6), 3.27 (1H, app. t, J = 5.2 Hz, H8), 3.07 
(2H, br s, NHCH2), 2.78 (1H, d, J = 4.3 Hz, H1), 2.73 (1H, br s, H7), 2.65 (1H, d, J = 5.2 Hz, H9), 
1.82 (1H, d, J = 10.2 Hz, H10a), 1.66–1.62 (2H, m, CH2), 1.51–1.25 (28H, m, 9 × CH2, t-Bu, H10s). 
13C NMR (125 MHz, CDCl3) δ 178.4, 177.2, 104.4, 81.4, 79.5, 78.8, 45.3, 45.2, 43.7, 43.4, 40.8, 32.7, 
31.9, 30.1, 29.8, 29.63, 29.56, 29.5 (2 × C), 29.4, 28.6, 26.9, 24.2. HRMS (ESI, m/z) for C26H43NO8 
[M + H]+ calc. 498.3061; found 498.3054. 
4.1.12. 8-endo-9-exo-Di[2ʹ-(2ʺ,3ʺ-bis-tert-butoxycarbonylguanidino)ethylcarbamoyl]-4-[11ʹ-(tert-
butoxycarbonylamino)undecyl]-3,5-dioxatricyclo[5.2.1.02,6]decane (20). 
A MW vial was charged with diacid 19 (21 mg, 0.004 mmol), EDCI (24 mg, 0.126 mmol), HOBt 
(1 mg, 0.01 mmol) and anhydrous CHCl3 (210 µL) and was stirred at ambient temperature for 30 min. 
Amine 22 (38 mg, 0.13 mmol) was then added and the reaction was irradiated for 30 min at 50 °C. 
The resulting homogenous clear liquid was diluted with CHCl3 (10 mL), washed with H2O (2 × 
5 mL), brine (5 mL), dried (MgSO4), filtered, and concentrated in vacuo to afford a colourless oil that 
was purified using flash column chromatography (20% EtOAc in pet. spirits-EtOAc) to give the title 
compound (14 mg, 32%) as a colourless oil. Rf = 0.75 (EtOAc). 1H NMR (500 MHz, CDCl3) δ 11.47–
11.44 (2H, m, 2 × NH), 8.67 (1H, br s, NH), 8.56 (1H, br s, NH), 8.04 (1H, t, J = 4.1 Hz, NH), 6.92 
(1H, br s, NH), 4.60 (1H, t, J = 4.8 Hz, H4), 4.50 (1H, br s, NH), 4.02 (1H, d, J = 5.7 Hz, H6), 3.95 
(1H, d, J = 5.7 Hz, H2), 3.60–3.56 (4H, m, 2 × NHCH2), 3.45–3.35 (4H, m, 2 × NHCH2), 3.11–3.07 
(2H, m, BocNHCH2), 2.94 (1H, app. t, J = 5.3 Hz, H8), 2.70 (1H, d, J = 4.1 Hz, H1), 2.57 (1H, br s, 
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H7), 2.45 (1H, d, J = 5.3 Hz, H9), 1.77 (1H, d, J = 9.7 Hz, H10a), 1.62–1.57 (2H, m, CH2), 1.50–1.43 
(50H, m, 2 × CH2, 5 × t-Bu, H10s), 1.36–1.24 (14H, m, 7 × CH2). 13C NMR (125 MHz, CDCl3) δ 
174.2, 172.1, 163.1, 162.7, 157.8, 157.0, 156.1, 153.2, 153.1, 104.1, 83.8, 83.6, 81.7, 80.1, 80.0, 79.1, 
79.0, 47.8, 44.4, 44.2, 43.0, 42.1, 40.8, 40.4, 40.1, 40.0, 33.0, 32.5, 32.1, 30.2, 29.8, 29.7, 29.6, 29.4, 
28.6, 28.38, 28.37, 28.20, 28.19, 27.0, 24.3, 22.8. HRMS (ESI, m/z) for C52H91N9O14 [M + H]+ calc. 
1066.6758; found 1066.6775. 
4.1.13. 4-[11ʹ-(Amino)undecyl]-3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-
dicarboxamidoethylguanidine hydrogen chloride (21).  
To a stirring solution of Boc-protected guanidine 20 (14 mg, 0.01 mmol) and MeOH (1 mL) was 
added dropwise AcCl (30 µL, 0.422 mmol), and the reaction was stirred for 48 h at ambient 
temperature. The reaction was concentrated in vacuo and co-evaporated with MeOH (2 × 0.5 mL), to 
afford the title compound (9 mg, 99%) as a colourless oil. 1H NMR (500 MHz, CD3OD) δ 4.66 (1H, t, 
J = 4.6 Hz, H4), 4.05 (1H, d, J = 5.5 Hz, H6), 4.00 (1H, d, J = 5.5 Hz, H2), 3.37–3.26 (4H, m, 2 × 
NHCH2), 3.21 (1H, app. t, J = 5.0 Hz, H8), 2.96–2.85 (6H, m, 3 × NHCH2), 2.62–2.61 (2H, m, H1, 
H7), 2.45 (1H, br s,, H9), 1.73 (1H, d, J = 10.3 Hz, H10a), 1.64–1.58 (4H, m, 2 × CH2), 1.48 (1H, d, J 
= 10.3 Hz,
 
H10s), 1.40–1.29 (16H, m, 8 × CH2). 13C NMR (125 MHz, CD3OD) δ 176.5, 174.6, 158.9 
(2 × C), 105.1, 82.8, 80.0, 47.7, 47.0, 45.1, 44.9, 41.93, 41.88, 40.0, 39.7, 39.6, 33.9, 32.7, 30.8, 
30.70, 30.67, 30.6, 30.5, 30.3, 29.2, 27.5, 25.2. HRMS (ESI, m/z) for C27H51N9O4 [M + 3H]3+ calc. 
189.4761; found 189.4766.  
4.1.14. Dimethyl 4-(11ʹ-aminoundecanyl)-3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-
dicarboxylate hydrogen chloride (23). 
To a stirring solution of Boc-protected amine 18 (511 mg, 0.97 mmol) and MeOH (10 mL) was added 
dropwise AcCl (700 µL, 9.85 mmol), and the reaction was stirred for 24 h at ambient temperature. 
The reaction mixture was concentrated in vacuo, co-evaporated with MeOH (2 × 0.5 mL) and the title 
compound was isolated (444 mg, 99%) as an off-white sticky residue. 1H NMR (500 MHz, CD3OD) 
δ 4.66 (1H, t, J = 4.8 Hz, H4), 4.00 (1H, d, J = 5.6 Hz, H2), 3.90 (1H, d, J = 5.6 Hz, H6), 3.71 (3H, s, 
Me), 3.70 (3H, s, Me), 3.21 (1H, app. t, J = 5.0 Hz, H8), 2.91 (2H, app. t, J = 7.6 Hz, CH2NH3), 2.64–
2.62 (2H, m, H1, H7), 2.56 (1H, br s, H9), 1.74 (1H, dd, J = 10.7, 1.5 Hz, H10a), 1.67–1.58 (4H, m, 2 
× CH2), 1.41–1.29 (17H, m, 8 × CH2, H10s). 13C NMR (125 MHz, CD3OD) δ 175.4, 174.0, 105.2, 
82.5, 80.0, 52.8, 52.6, 46.6, 46.2, 44.9, 44.5, 40.8, 33.8, 32.4, 30.62, 30.57 (3 × C), 30.5, 30.2, 28.6, 
27.4, 25.2. HRMS (ESI, m/z) for C23H39NO6 [M + H]+ calc. 426.2850; found 426.2847. 
4.1.15. Dimethyl 4-[11ʹ-(6ʺ-bromo-1ʺ,3ʺ-dioxo-1H-benzo[de]isoquinoline-2(3H))undecyl]-3,5-
dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-dicarboxylate (25). 
A 10 mL microwave vial was charged with 4-bromo-1,8-naphthalic anhydride (264 mg, 0.953 mmol), 
norbornane hydrochloride 23 (444 mg, 0.961 mmol), Et3N (140 µL, 1.00 mmol) and EtOH (3 mL) 
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and heated to 100 °C using microwave irradiation for 45 min. The orange slurry was diluted with H2O 
(30 mL) and extracted with EtOAc (3 × 30 mL). The combined organic phase was washed with 0.1 M 
HCl (30 mL), sat. NaHCO3 (30 mL), brine (30 mL), dried (MgSO4), filtered and concentrated in 
vacuo to give the title compound (649 mg, 99%) as an orange oil. 1H NMR (270 MHz, CDCl3) δ 8.64 
(1H, dd, J = 7.4, 1.2 Hz, H9ʺ), 8.55 (1H, dd, J = 8.6, 1.2 Hz, H7ʺ), 8.40 (1H, d, J = 7.8 Hz, H4ʺ), 8.02 
(1H, d, J = 7.8 Hz, H5ʺ), 7.83 (1H, dd, J = 8.6, 7.4 Hz, H8ʺ), 4.64 (1H, t, J = 4.9 Hz, H4), 4.18–4.12 
(2H, m, H11ʹ), 4.02 (1H, d, J = 5.5 Hz, H2), 3.89 (1H, d, J = 5.5 Hz, H6), 3.70 (6H, s, 2 × Me), 3.23 
(1H, app. t, J = 4.9 Hz, H8), 2.71 (1H, d, J = 4.9 Hz, H9), 2.65–2.64 (2H, m, H1, H7), 1.78 (1H, dd, J 
= 11.0, 1.5 Hz, H10s), 1.74–1.58 (4H, m, H1ʹ, H10ʹ), 1.42–1.25 (17H, m, 8 × CH2, H10s). 13C NMR 
(67.5 MHz, CDCl3) δ 174.1, 172.9, 163.74, 163.73, 133.3, 132.1, 131.3, 131.2, 130.8, 130.3, 129.1, 
128.2, 123.3, 122.4, 104.3, 81.4, 78.9, 52.5, 52.3, 45.4, 45.2, 43.8, 43.4, 40.7, 32.9, 31.8, 29.7 (2 × C), 
29.62, 29.60, 29.5 (2 × C), 28.2, 27.2, 24.3. HRMS (ESI, m/z) for C35H4279BrNO8 [M + Na]+ calc. 
706.1986; found 706.1972. 
4.1.16. Dimethyl 4-[11ʹ-(6ʺ-propylamino-1ʺ,3ʺ-dioxo-1H-benzo[de]isoquinoline-2(3H))undecyl]-
3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-dicarboxylate (26). 
A stirring solution of 4-bromo naphthalimide norbornane 25 (28 mg, 0.041 mmol), Pd2(dba)3·CHCl3 
(2 mg, 0.002 mmol), Xantphos (1 mg, 0.002 mmol), propylamine (5 drops) and Cs2CO3 (40 mg, 
0.123 mmol) in PhMe (410 µL) was heated at 70 °C for 24 h. The solvent was removed in vacuo and 
the resulting residue was loaded onto SiO2 and purified using column chromatography (2% MeOH in 
1:4 EtOAc in pet. spirits) to give the title compound (23 mg, 88%) as a yellow oil. Rf = 0.19 (2% 
MeOH in 1:4 EtOAc in pet. spirits). 1H NMR (400 MHz, CDCl3) δ 8.57 (1H, dd, J = 7.4, 1.1 Hz, 
H9ʺ), 8.45 (1H, d, J = 8.5 Hz, H4ʺ), 8.08 (1H, dd, J = 8.4, 1.1 Hz, H7ʺ), 7.61 (1H, dd, J = 8.4, 7.4 Hz, 
H8ʺ), 6.72 (1H, d, J = 8.5 Hz, H5ʺ), 5.26–5.25 (1H, m, NH), 4.65 (1H, t, J = 4.9 Hz, H4), 4.16–4.12 
(2H, m, H11ʹ), 4.02 (1H, d, J = 5.7 Hz, H2), 3.90 (1H, dd, J = 5.7, 1.4 Hz, H6), 3.70 (3H, s, Me), 3.69 
(3H, s, Me), 3.40–3.35 (2H, m, NHCH2), 3.22 (1H, app. t, J = 5.1 Hz, H8), 2.72 (1H, d, J = 4.9 Hz, 
H9), 2.65–2.64 (2H, m, H1, H7), 1.88–1.76 (3H, m, CH2CH3, H10a), 1.74–1.67 (2H, m, H10ʹ), 1.64–
1.59 (2H, m, H1ʹ), 1.43–1.24 (17H, m, 8 × CH2, H10s), 1.11 (3H, t, J = 7.4 Hz, CH3). 13C NMR (100 
MHz, CDCl3) δ 174.1, 172.9, 164.8, 164.3, 149.5, 134.6, 131.2, 130.8, 125.8, 124.8, 123.4, 120.3, 
110.5, 104.5, 104.4, 81.4, 78.9, 52.5, 52.3, 45.6, 45.4, 45.2, 43.8, 43.4, 40.4, 32.9, 31.8, 29.69, 29.67 
(2 × C), 29.6 (2 × C), 29.5, 28.4, 27.3, 24.4, 22.4, 11.8. HRMS (ESI, m/z) for C38H50N2O8 [M + H]+ 
calc. 663.3640; found 663.3648. 
4.1.17. 4-[11ʹ-(6ʺ-Propylamino-1ʺ,3ʺ-dioxo-1H-benzo[de]isoquinoline-2(3H))undecyl]-3,5-
dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-dicarboxylic acid (27). 
A biphasic solution of ester 26 (434 mg, 0.655 mmol) in 2 M NaOH/THF (1:4, 7 mL) was stirred at 
ambient temperature for 16 h. The reaction mixture was extracted with CH2Cl2 (2 × 15 mL) and the 
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isolated aqueous phase was acidified to pH = 1 using 2 M HCl and extracted with EtOAc (3 × 15 
mL). The combined organic phase was washed with brine (15 mL), dried (MgSO4), filtered and 
concentrated in vacuo to afford the title compound (366 mg, 88%) as an orange solid. m.p. 94–95 °C. 
1H NMR (500 MHz, CDCl3) δ 8.56 (1H, dd, J = 7.5, 1.1 Hz, H9ʺ), 8.44 (1H, d, J = 8.5 Hz, H4ʺ), 8.08 
(1H, dd, J = 8.5, 1.1 Hz, H7ʺ), 7.58 (1H, dd, J = 8.5, 7.5 Hz, H8ʺ), 6.69 (1H, d, J = 8.5 Hz, H5ʺ), 4.68 
(1H, t, J = 4.8 Hz, H4), 4.14–4.11 (2H, m, H11ʹ), 4.05 (2H, br s, H2, H6), 3.37 (2H, app. t, J = 7.3 Hz, 
NHCH2), 3.28 (1H, app. t, J = 5.2 Hz, H8), 2.79 (1H, d, J = 4.3 Hz, H7), 2.73 (1H, br s, H1), 2.66 
(1H, d, J = 5.2 Hz, H9), 1.85–1.81 (3H, m, CH2, H10a), 1.72–1.59 (4H, m, 2 × CH2), 1.39–1.21 (17H, 
m, 8 × CH2, H10s), 1.10 (3H, t, J = 7.4 Hz, CH3). 13C NMR (125 MHz, CDCl3) δ 178.1, 176.9, 164.9, 
164.5, 149.7, 134.8, 131.4, 129.9, 126.0, 124.8, 123.2, 120.2, 110.1, 104.5, 104.4, 81.3, 78.8, 45.6, 
45.2, 45.1, 43.7, 43.4, 40.5, 32.7, 31.9, 29.8, 29.64, 29.58, 29.55, 29.4 (2 × C), 28.4, 27.3, 24.2, 22.4, 
11.8. HRMS (ESI, m/z) for C36H46N2O8 [M − H]− calc. 633.3181; found 633.3190. 
4.1.18. 8-endo-9-exo-Di[2ʹ-(2ʺ,3ʺ-bis-tert-butoxycarbonylguanidino)ethylcarbamoyl]-4-[11ʹ-(6ʺ-
propylamino-1ʺ,3ʺ-dioxo-1H-benzo[de]isoquinoline-2(3H))undecyl]-3,5-
dioxatricyclo[5.2.1.02,6]decane (28). 
A solution of diacid 27 (285 mg, 0.449 mmol), EDCI (260 mg, 1.35 mmol), HOBt (6 mg, 0.05 mmol), 
aminoethylguanidine 22 (423 mg, 1.40 mmol) and anhydrous DMF (6 mL) was stirred at ambient 
temperature for 2 d under an inert atmosphere. The reaction mixture was diluted with EtOAc (25 mL) 
and washed with H2O (15 mL), brine (3 × 15 mL), dried (MgSO4), filtered and concentrated in vacuo 
to give a yellow oil. The crude material was purified using column chromatography (EtOAc) to afford 
the title compound (444 mg, 82%) as a yellow solid. Rf = 0.50 (EtOAc). m.p. 98–99 °C. ɸf = 
0.89 (DMSO). 1H NMR (500 MHz, CDCl3) δ 11.48 (1H, br s, NH), 11.45 (1H, br s, NH), 8.63 (1H, t, 
J = 6.1 Hz, NH), 8.57 (1H, dd, J = 7.4, 1.0 Hz, H9ʺ), 8.51 (1H, t, J = 5.8 Hz, NH), 8.45 (1H, d, J = 
8.5 Hz, H4ʺ), 8.09 (1H, dd, J = 8.5, 1.0 Hz, H7ʺ), 8.01 (1H, t, J = 4.1 Hz, NH), 7.61 (1H, dd, J = 8.5, 
7.4 Hz, H8ʺ), 6.86 (1H, t, J = 5.3 Hz, NH), 6.72 (1H, d, J = 8.5 Hz, H5ʺ), 5.29 (1H, t, J = 5.0 Hz, 
NH), 4.60 (1H, t, J = 4.9 Hz, H4), 4.15–4.12 (2H, m, H11ʹ), 4.02 (1H, d, J = 5.5 Hz, H6), 3.94 (1H, d, 
J = 5.5 Hz, H2), 3.60–3.52 (4H, m, 2 × NHCH2), 3.44–3.36 (6H, m, 3 × NHCH2), 2.94 (1H, app. t, J = 
5.2 Hz, H8), 2.78 (1H, br s, H7), 2.70 (1H, d, J = 4.1 Hz, H1), 2.44 (1H, d, J = 5.2 Hz, H9), 1.87–
1.80 (2H, m, CH2), 1.77 (1H, d, J = 9.5 Hz, H10a), 1.72–1.67 (2H, m, CH2), 1.62–1.57 (2H, m, CH2), 
1.50–1.48 (37H, m, 4 × t-Bu, H10s), 1.42–1.24 (16H, m, 8 × CH2), 1.10 (3H, t, J = 7.4 Hz, CH3). 
13C NMR (125 MHz, CDCl3) δ 174.2, 172.1, 164.8, 164.3, 163.5, 163.0, 157.9, 157.1, 153.2, 149.5, 
134.6, 131.2, 129.9, 125.8, 124.8, 123.4, 120.3, 110.5, 104.5, 104.2, 83.7, 83.4, 81.6, 79.9, 79.7, 79.0, 
47.8, 45.6, 44.30, 44.25, 42.3, 40.4, 40.2, 40.04, 39.97, 33.0, 32.5, 29.74, 29.71, 29.69, 29.66, 29.6, 
28.40, 28.38, 28.3, 28.20, 28.19, 27.3, 24.4, 22.4, 11.8. HRMS (ESI, m/z) for C62H94N10O14 [M + H]+ 
calc. 1203.7024; found 1203.7040. 
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4.1.19. 4-[11ʹ-(6ʺ-Propylamino-1ʺ,3ʺ-dioxo-1H-benzo[de]isoquinoline-2(3H))undecyl]-3,5-
dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-dicarboxamidoethylguanidine hydrogen chloride 
(29). 
To a stirring solution of Boc-protected guanidine 28 (87 mg, 0.072 mmol) and MeOH (720 µL) was 
added dropwise AcCl (200 µL, 2.81 mmol), and the reaction was stirred for 2 d at ambient 
temperature. The reaction mixture was concentrated in vacuo, co-evaporated with MeOH (2 × 0.5 
mL) and the title compound was isolated (61 mg, 97%) as an off-white sticky residue. m.p. 122–159 
°C (slow decomposition). ɸf = 0.88 (DMSO) and 0.16 (H2O). 1H NMR (500 MHz, CD3OD) δ 8.55 
(1H, dd, J = 8.5, 1.1 Hz, H9ʺ), 8.50 (1H, dd, J = 7.5, 1.1 Hz, H7ʺ), 8.35 (1H, d, J = 8.7 Hz, H4ʺ), 7.63 
(1H, dd, J = 8.5, 7.5 Hz, H8ʺ), 6.78 (1H, d, J = 8.7 Hz, H5ʺ), 4.65 (1H, t, J = 4.7 Hz, H4), 4.12–4.09 
(2H, m, H11ʹ), 4.05 (1H, d, J = 5.7 Hz, H6), 3.99 (1H, d, J = 5.7 Hz, H2), 3.43–3.28 (10H, m, 5 × 
NHCH2), 3.23 (1H, app. t, J = 5.1 Hz, H8), 2.62–2.61 (2H, m, H1, H7), 2.44 (1H, br s, H9), 1.85–1.78 
(2H, m, CH2), 1.73 (1H, d, J = 10.0 Hz, H10a), 1.70–1.66 (2H, m, CH2), 1.61–1.57 (2H, m, CH2), 
1.47 (1H, d, J = 10.0 Hz, H10s), 1.40–1.28 (16H, m, 8 × CH2), 1.07 (3H, t, J = 7.4 Hz, CH3). 13C 
NMR (125 MHz, CD3OD) δ 176.5, 174.6, 166.3, 165.8, 158.9 (2 × C), 152.8, 136.1, 132.2, 131.3, 
129.4, 125.4, 123.4, 121.9, 109.1, 105.11, 105.09, 82.8, 79.9, 47.8, 46.8, 46.2, 45.1, 44.9, 42.0, 41.9, 
41.0, 39.7, 39.6, 33.9, 32.7, 30.6 (4 × C), 30.5, 30.4, 29.1, 28.1, 25.2, 22.7, 11.9. HRMS (ESI, m/z) for 
C42H62N10O6 [M + 2H]2+ calc. 402.2500; found 402.2506. 
4.1.20. Dimethyl 4-[11ʹ-(7ʺ-nitrobenzo[c][1,2,5]oxadiazol-4ʺ-amino)undecyl]-3,5-
dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-dicarboxylate (31). 
A solution of norbornane hydrochloride 23 (371 mg, 0.803 mmol), 4-nitrobenz-2-oxa-1,3-diazole 
chloride (160 mg, 0.803 mmol) and Et3N (170 µL, 1.22 mmol) in MeOH (8 mL) was stirred at 
ambient temperature for 24 h. The reaction mixture was concentrated under reduced pressure then 
diluted with EtOAc (20 mL). The organic phase was washed with 0.1 M HCl (10 mL), sat. NaHCO3 
(10 mL), brine (10 mL), dried (MgSO4), filtered and concentrated in vacuo. The orange residue was 
purified using column chromatography (10% EtOAc in CH2Cl2) to give the title compound (320 mg, 
68%) as a dark orange viscous oil. Rf = 0.9 (10% EtOAc in CH2Cl2). 1H NMR (500 MHz, CDCl3) δ 
8.48 (1H, d, J = 8.6 Hz, H6ʺ), 6.33 (1H, t, J = 4.7 Hz, NH), 6.17 (1H, d, J = 8.6 Hz, H5ʺ), 4.65 (1H, t, 
J = 4.8 Hz, H4), 4.02 (1H, d, J = 5.6 Hz, H6), 3.94 (1H, d, J = 5.6 Hz, H2), 3.70 (3H, s, Me), 3.69 
(3H, s, Me), 3.50–3.46, (2H, m, H11ʹ), 3.22 (1H, app. t, J = 5.2 Hz, H8), 2.71 (1H, d, J = 4.5 Hz, H7), 
2.65–2.64 (2H, m, H1, H9), 1.83–1.75 (3H, m, H10ʹ, H10a), 1.64–1.60 (2H, m, H1ʹ), 1.48–1.42 (2H, 
m, H9ʹ), 1.39–1.26 (15H, m, H10s, 7 × CH2). 13C NMR (125 MHz, CDCl3) δ 174.1, 172.9, 144.4, 
144.1, 144.0, 136.7, 123.9, 104.3, 98.6, 81.3, 78.9, 52.5, 52.3, 45.4, 45.1, 44.1, 43.7, 43.4, 32.9, 31.7, 
29.60, 29.57, 29.5 (3 × C), 29.3, 28.6, 27.1, 24.3. HRMS (ESI, m/z) for C29H40N4O9 [M + H]+ calc. 
589.2868; found 589.2883. 
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4.1.21. 4-[11ʹ-(7ʺ-Nitrobenzo[c][1,2,5]oxadiazol-4ʺ-amino)undecyl]-3,5-
dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-dicarboxylic acid (32). 
A biphasic solution of ester 31 (259 mg, 0.440 mmol) in 2 M NaOH/THF (1:4, 3 mL) was stirred at 
ambient temperature for 16 h. The reaction mixture was extracted with CH2Cl2 (2 × 5 mL) and the 
aqueous phase was isolated and acidified to pH = 1 using 2 M HCl and then extracted with EtOAc (3 
× 15 mL). The combined organic phase was washed with brine (15 mL), dried (MgSO4), filtered and 
concentrated in vacuo to afford the title compound (193 mg, 78%) as an orange solid. m.p. 98–99 °C. 
1H NMR (400 MHz, DMSO-d6) δ 9.55 (1H, t, J = 5.3 Hz, NH), 8.50 (1H, d, J = 9.1 Hz, H6ʺ), 6.40 
(1H, d, J = 9.1 Hz, H5ʺ), 4.61 (1H, t, J = 4.8 Hz, H4), 3.96 (1H, d, J = 5.8 Hz, H6), 3.88 (1H, d, J = 
5.8 Hz, H2), 3.45–3.44, (2H, m, H11ʹ), 3.00 (1H, app. t, J = 5.5 Hz, H8), 2.52 (1H, d, J = 4.6 Hz, H7), 
2.45 (1H, br s, H1), 2.40 (1H, d, J = 5.5 Hz, H9), 1.70–1.63 (2H, m, H10ʹ), 1.59 (1H, d, J = 9.6 Hz, 
H10a), 1.54–1.49 (2H, m, H1ʹ), 1.37–1.19 (17H, m, H10s, 8 × CH2). 13C NMR (100 MHz, DMSO-d6) 
δ 174.6, 173.3, 145.2, 144.4, 144.2, 138.0, 120.5, 103.2, 99.1, 80.7, 78.2, 45.0, 44.4, 43.4, 43.2, 42.6, 
32.3, 31.2, 28.9 (5 × C), 28.7, 27.6, 26.4, 23.7. HRMS (ESI, m/z) for C27H36N4O9 [M − H]− calc. 
559.2410; found 559.2424. 
4.1.22. 8-endo-9-exo-Di[2ʹ-(2ʺ,3ʺ-bis-tert-butoxycarbonylguanidino)ethylcarbamoyl]-4-[11ʹ-(7ʺ-
nitrobenzo[c][1,2,5]oxadiazol-4ʺ-amino)undecyl]-3,5-dioxatricyclo[5.2.1.02,6]decane (33). 
A solution of diacid 32 (200 mg, 0.357 mmol), EDCI (222 mg, 1.16 mmol), HOBt (5 mg, 0.04 mmol), 
aminoethylguanidine 22 (339 mg, 1.12 mmol) and anhydrous DMF (5.1 mL) was stirred at ambient 
temperature for 3 d under an inert atmosphere. The reaction mixture was diluted with EtOAc (25 mL) 
and washed with H2O (15 mL), brine (3 × 15 mL), dried (MgSO4), filtered and concentrated in vacuo. 
The crude material was purified using flash column chromatography (50% EtOAc in CH2Cl2) and the 
title compound (263 mg, 65%) was isolated as an orange solid. Rf = 0.3 (50% EtOAc in CH2Cl2). m.p. 
117–124 °C (slow decomposition). ɸf = 0.55 (DMSO). 1H NMR (500 MHz, CDCl3) δ 11.48 (1H, br s, 
NH), 11.44 (1H, br s, NH), 8.64 (1H, t, J = 6.1 Hz, NH), 8.51–8.49 (2H, m, H6ʺ, NH), 8.03 (1H, t, J = 
4.1 Hz, NH), 6.87 (1H, t, J = 5.2 Hz, NH), 6.32 (1H, t, J = 5.2 Hz, NH), 6.17 (1H, d, J = 8.7 Hz, H5ʺ), 
4.61 (1H, t, J = 4.7 Hz, H4), 4.04 (1H, d, J = 5.6 Hz, H6), 3.95 (1H, d, J = 5.6 Hz, H2), 3.60–3.35 
(10H, m, 5 × NHCH2), 2.93 (1H, app. t, J = 5.2 Hz, H8), 2.70 (1H, d, J = 4.1 Hz, H1), 2.58 (1H, br s, 
H7), 2.45 (1H, d, J = 5.2 Hz, H9), 1.83–1.76 (3H, m, H10ʹ, H10a), 1.61–1.58 (2H, m, H1ʹ), 1.53–1.43 
(37H, m, H10s, 4 × t-Bu), 1.38–1.27 (16H, m, 8 × CH2). 13C NMR (125 MHz, CDCl3) δ 174.2, 172.0, 
163.5, 163.0, 157.9, 157.1, 153.2 (2 × C), 144.4, 144.04, 144.00, 136.6, 124.1, 104.1, 98.6, 83.7, 83.4, 
81.7, 79.9, 79.7, 79.0, 47.9, 44.3, 44.2, 44.1, 43.0, 42.3, 40.2, 40.1, 40.0, 32.9, 32.5, 29.61, 29.56, 
29.54, 29.51, 29.48, 29.3, 28.7, 28.41, 28.39, 28.21, 28.20, 27.1, 24.2. HRMS (ESI, m/z) for 
C53H84N12O15 [M + H]+ calc. 1129.6252; found 1129.6265. 
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4.1.23. 4-[11ʹ-(7ʺ-Nitrobenzo[c][1,2,5]oxadiazol-4ʺ-amino)undecyl]-3,5-
dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-dicarboxamidoethylguanidine hydrogen chloride 
(34).  
To a stirring solution of Boc-protected guanidine 33 (89 mg, 0.079 mmol) and MeOH (790 µL) was 
added dropwise AcCl (230 µL, 3.23 mmol), and the reaction was stirred for 2 d at ambient 
temperature. The reaction mixture was concentrated in vacuo, co-evaporated with MeOH (2 × 0.5 
mL) and the title compound was isolated (60 mg, 95%) as an orange solid. m.p. 121–124 °C. ɸf = 0.55 
(DMSO) and 0.02 (H2O). 1H NMR (500 MHz, CD3OD) δ 8.53 (1H, d, J = 8.8 Hz, H6ʺ), 6.35 (1H, d, J 
= 8.8 Hz, H5ʺ), 4.64 (1H, t, J = 4.7 Hz, H4), 4.04 (1H, d, J = 5.6 Hz, H6), 3.99 (1H, d, J = 5.6 Hz, 
H2), 3.55–3.52 (2H, m, H11ʹ), 3.40–3.29, (8H, m, 4 × CH2NH), 3.22 (1H, app. t, J = 5.0 Hz, H8), 
2.62–2.61 (2H, m, H1, H7), 2.44 (1H, br s, H9), 1.80–1.75 (2H, m, H10ʹ), 1.72 (1H, d, J = 10.4 Hz, 
H10a), 1.59–1.55 (2H, m, H1ʹ), 1.48–1.28 (17H, m, H10s, 8 × CH2). 13C NMR (125 MHz, CD3OD) δ 
176.5, 174.6, 158.8 (2 × C), 146.7, 145.9, 145.6, 138.6, 122.9, 105.1, 99.5, 82.8, 79.9, 47.7, 46.9, 
45.1, 44.9, 44.7, 42.0, 41.9, 39.7, 39.6, 33.9, 32.7, 30.61, 30.57, 30.51 (2 × C), 30.49, 30.3, 29.2, 28.0, 
25.2. HRMS (ESI, m/z) for C33H52N12O7 [M + 2H]2+ calc. 365.2114; found 365.2115. 
 
4.2. Disk Diffusion Assay. A stock solution of 10 mg/mL was made for each compound under 
observation using DMSO as a solvent. Each stock solution was then diluted 1:2 to bring the 
concentration to 5 mg/mL in DMSO. The diluted solutions were then filter-sterilised using a 0.2-µm 
nylon filter, and 10 µL of the 5 mg/mL stock was pipetted onto a blank disk (i.e. 50 µg/disk; Oxoid 
Limited, Hampshire, UK). Suspensions of all bacterial isolates were adjusted to a 0.5 McFarland 
standard (in 0.9% NaCl) before they were swabbed onto nutrient agar plates. The controls used were a 
10 µg Colistin disk (sulphate, Oxoid), 10 µL of DMSO and a plate swabbed with saline from the 
dispenser used. 
 
4.3. Minimum Inhibitory Concentration (MIC) determination. Bacteria were obtained either from 
American Type Culture Collection (ATCC; Manassas, VA, USA) or Network on Antimicrobial 
Resistance in Staphylococcus aureus (NARSA) as listed in Table S1. Bacteria were cultured in 
Nutrient broth (NB; Bacto Laboratories, catalogue No. 234000) or Mueller-Hinton broth (MHB; 
Bacto Laboratories, catalogue No. 211443) at 37 °C overnight with shaking (~180 RPM). A sample of 
each culture was diluted 50-fold in fresh MHB and incubated at 37 °C for 1.5–3 h with shaking (~180 
RPM). Compound stock solutions were prepared as 10 mg/mL in DMSO and Colistin was dissolved 
in milli-Q water at 5.12 mg/mL.  The compounds, at twice the final desired concentration, were 
serially diluted 2-fold across the wells of 96–well plates (Non-Binding Surface (NBS), Corning, 
catalogue No. 3641). Mid-log phase bacterial cultures (after 1.5–3 h incubation) were diluted to give a 
final cell density of 5×105 colony forming units (CFU)/mL when adding 50 µL to each well giving a 
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final compound concentration range of 32 µg/mL to 0.015 µg/mL (DMSO ≤ 1%). MICs were 
determined visually after 18–20 h of incubation at 37 °C, with the MIC defined as the lowest 
compound concentration at which no bacterial growth was visible. Determined MIC values are the 
result of two independent experiments of n = 2, giving a final dataset of n = 4. 
4.4. Cytotoxicity evaluation.  HEK293 (ATCC CRL-1573, human embryonic kidney) cells were 
seeded as 3000 cells per well in a 384-well plate in DMEM medium (GIBCO-Invitrogen #11995-
073), in which 10% of FBS was added. Cells were incubated for 24 h at 37 °C, 5% CO2 to allow cells 
to attach to the plates. A concentration series of compounds was then added into each well. The cells 
were incubated with the compounds for 24 h at 37 °C, 5% CO2. After the incubation, 10 µM resazurin 
(dissolved in PBS) was added to each well. The plates were then incubated for 2 h at 37 °C, 5% CO2. 
The fluorescence intensity was read using Polarstar Omega with excitation/emission 560/590. The 
data was analysed by Prism software. Results are presented as the average percentage of control ± SD 
for each set of duplicate wells.  
4.5. Microscopy. Escherichia coli (ATCC© 25922TM, USA) and Staphylococcus aureus 
(Staphylococcus aureus subsp. aureus Rosenbach (ATCC® 43300™ MRSA), USA) were grown in 
50 mL of Luria-Bertani (LB) broth at 37 °C with gentle shaking overnight. S. aureus and E. coli were 
incubated with for 20 min at 37 ºC with 10 µg/mL of fluorescent compound (29, 34, 35 or 36) in LB 
broth. For time dependent assessment, E. coli were incubated with 10 µg/mL of compound 34 for 
5 min, 30 min, 1 h, 2 h, 4 h and 18 h. S. aureus were fixed in 4% paraformaldehyde for 20 min before 
being wet mounted onto slides for visualisation. Imaging was performed on a Nikon A1+ confocal 
microscope (Nikon, Japan) using a 60× object with excitation at 488 nm and emissions detected at 
500–550 nm by a GaAsP PMT detector. 3D reconstruction and rendering were performed using NIS 
elements software (Nikon, Japan).  
4.6. Modelling.  GROMACS version 2016.1 molecular dynamics package[69] in conjunction with the 
GROMOS 54A7 force field[70] was used for all MD simulations. Water was represented explicitly 
using the simple point charge (SPC) model.[71] Parameters for norbornane molecules prepared in the 
study were determined by the Automated Topology Builder.[72] Each system was simulated under 
periodic boundary conditions in a rectangular simulation box with a timestep of 2 fs. The temperature 
of the system was maintained by coupling each component of the system to an external temperature 
bath at 310 K with a coupling constant of τT = 0.1 ps using a velocity rescaling thermostat. The 
pressure was  maintained at 1 bar by weakly coupling  the system to a semi-isotropic pressure bath 
using an isothermal compressibility of 4.5 × 10–5 bar–1 and a coupling  constant of τP = 0.5 ps. During 
the simulations, the length of all bonds in all non-water molecules were constrained using the LINCS 
algorithm.[73] The SETTLE algorithm[74] was used to constrain the geometry of water molecules. 
Electrostatic interactions were calculated using particle mesh Ewald summation and nonbonded 
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interactions were calculated with a cut-off of 1.0 nm. Both were updated each timestep. All images 
and videos were prepared in VMD.[74] 
Aggregation simulations were conducted on bisamine (8), bisguanidine (2), benzylguanidine (7) and 
naphthalimide (29) species. Each simulation system consisted of 10 molecules of norbornane based 
compound, 20 chloride ions and 15,000 water molecules. Solute molecules were randomly positioned 
in a 9 × 9 × 9 nm box, to which water was then added. 1000 steps of energy minimisation, then 500 ps 
under an NPT ensemble was simulated for each species. Finally 300 ns, 400 ns, 200 ns, 200 ns long 
simulations was conducted for 8, 2, 7 and 29 respectively using an NVT ensemble until a single 
aggregate formed. To construct the aggregate for use in the bilayer simulations, the same procedure 
was followed on a system comprising of 200 molecules of 2, 400 chloride ions and 30,000 water 
molecules in a 15 × 15 × 15 box. The NVT ensemble was simulated for 100 ns.      
The starting coordinates of the model membrane used in the bilayer simulations were taken from 
Anandan et al.[75]. This represents the inner membrane of a Gram-negative bacteria. The outer 
membrane was not modelled as the structure of the peptidoglycan layer remains elusive. The model 
membrane is composed of 80% (408 molecules) of 1-palmitoyl-2-palmitoleyl-sn-glycero-3-
phophoethanolamine (PPoPE) and 20% (104 molecules) of 1,2-dimyristoyl-sn-glycero-3-phospho-
(1’-rac)-glycerol (DMPG). The membrane in Anandan et al. contained both ᴅ and ʟ-enantiomers of 
the DMPG head group; this was corrected in this study so that only the naturally occurring ʟ-
enantiomer was modelled. The model also contained 31,457 water molecules, 260 sodium ions and 
156 chloride ions. After 5000 steps of energy minimisation, the system was equilibration using an 
NPT ensemble for 100 ns.        
The largest aggregate of 2 (28 molecules), was placed with random orientation in the water 
surrounding the model membrane. The addition of more water molecules was necessary to 
accommodate the aggregate; ca. 11,500 additional water molecules were added, expanding the system 
size in the direction normal to the bilayer plane. Three replicates were then energy minimised for 
10000 steps each, then were simulated using an NPT ensemble. The first replicate was simulated for 
780 ns; the second and third replicates were simulated for 500 ns.     
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Highlights 
 
• Antibacterial norbornane based amphiphiles with MIC as low as 0.25 μg/mL. 
• Fluorescent microscopy of fluorophore-tagged analogues shows membrane localisation.  
• Molecular modelling indicates rapid aggregation prior to membrane insertion.  
 
